All In Biotech

NDA 020833 · Glaxo Grp LTD

Flovent Diskus 250

Fluticasone Propionate · Inhalation

Last checked: Nov 20, 2026Latest source record: Jan 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Sep 29, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

738

240 Phase 3, 19 recruiting

FAERS reports

30,966

17,995 serious, 1,765 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 28, 2026.

Fluticasone Propionate DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use Fluticasone Propionate DISKUS is NOT indicated for the relief of acute bronchospasm. Fluticasone Propionate DISKUS is an inhaled corticosteroid (ICS) indicated for: Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. ( 1 ) Important limitation: Not indicated for relief of acute bronchospasm. ( 1 )

Mechanism: Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. Inflammation is an important component in the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 29, 2000 Original approval · Type 3 - New Dosage Form ReviewLetter
3 products under this application
  • FLOVENT DISKUS 250 · FLUTICASONE PROPIONATE 0.25MG/INH · POWDER, INHALATION · Prescription
  • FLOVENT DISKUS 50 · FLUTICASONE PROPIONATE 0.05MG/INH · POWDER, INHALATION · Prescription
  • FLOVENT DISKUS 100 · FLUTICASONE PROPIONATE 0.1MG/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.

All 738 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,500
  • drug ineffective2,452
  • headache2,353
  • fatigue2,173
  • off label use1,942
  • pain1,915
  • nausea1,881
  • cough1,807
  • asthma1,684
  • diarrhoea1,667
  • product dose omission issue1,518
  • pneumonia1,477

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004383
2005329
2006341
2007414
2008430
2009383
2010584
2011918
20121,016
2013372
2014484
20151,120
20161,530
20171,239
20181,698
20191,718
20202,072
20211,883
20222,236
20232,733
20243,322
20253,319
20262,441

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,187 on PubMed

Sponsor: GSK · Also marketed as Flovent Diskus 50, Flovent Diskus 100

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.